Duncker Streett & Co’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$16.2M Buy
74,644
+2,632
+4% +$584K 3.09% 5
2025
Q4
$16.5M Buy
72,012
+735
+1% +$167K 2.92% 7
2025
Q3
$16.5M Buy
71,277
+10,721
+18% +$2.18M 2.88% 7
2025
Q2
$11.2M Buy
60,556
+408
+0.7% +$75.8K 2.05% 12
2025
Q1
$12.6M Buy
60,148
+15,559
+35% +$3.02M 2.5% 5
2024
Q4
$7.92M Sell
44,589
-311
-0.7% -$57.2K 1.47% 14
2024
Q3
$8.87M Sell
44,900
-14
-0% -$2.61K 1.62% 13
2024
Q2
$7.7M Buy
44,914
+278
+0.6% +$46K 1.48% 14
2024
Q1
$8.13M Sell
44,636
-983
-2% -$169K 1.6% 14
2023
Q4
$7.07M Sell
45,619
-101
-0.2% -$14.7K 1.49% 15
2023
Q3
$6.81M Sell
45,720
-72
-0.2% -$10.6K 1.59% 9
2023
Q2
$6.17M Sell
45,792
-225
-0.5% -$33K 1.38% 14
2023
Q1
$7.33M Sell
46,017
-972
-2% -$149K 1.75% 8
2022
Q4
$7.59M Sell
46,989
-79
-0.2% -$12.1K 1.83% 6
2022
Q3
$6.32M Sell
47,068
-27
-0.1% -$3.87K 1.64% 7
2022
Q2
$7.21M Sell
47,095
-507
-1% -$77.5K 1.73% 7
2022
Q1
$7.72M Sell
47,602
-4,872
-9% -$708K 1.53% 9
2021
Q4
$7.11M Buy
52,474
+117
+0.2% +$13.8K 1.22% 15
2021
Q3
$5.65M Buy
52,357
+1,451
+3% +$166K 1.07% 16
2021
Q2
$5.73M Buy
50,906
+82
+0.2% +$9.23K 1.06% 16
2021
Q1
$5.5M Buy
50,824
+301
+0.6% +$32.2K 1.05% 20
2020
Q4
$5.41M Buy
50,523
+1,081
+2% +$104K 1.05% 21
2020
Q3
$4.33M Buy
49,442
+88
+0.2% +$8.29K 0.95% 27
2020
Q2
$4.85M Sell
49,354
-2,148
-4% -$189K 1.15% 16
2020
Q1
$3.92M Sell
51,502
-297
-0.6% -$25.3K 1.05% 21
2019
Q4
$4.59M Sell
51,799
-1,315
-2% -$109K 0.96% 23
2019
Q3
$4.02M Sell
53,114
-6,117
-10% -$419K 0.94% 26
2019
Q2
$4.31M Sell
59,231
-864
-1% -$67.9K 0.97% 18
2019
Q1
$4.84M Sell
60,095
-4,328
-7% -$354K 1.12% 15
2018
Q4
$5.94M Sell
64,423
-2,546
-4% -$224K 1.59% 7
2018
Q3
$6.33M Buy
66,969
+19
+0% +$1.8K 1.44% 8
2018
Q2
$6.2M Sell
66,950
-3,654
-5% -$357K 1.54% 7
2018
Q1
$6.68M Buy
70,604
+6,414
+10% +$705K 1.69% 7
2017
Q4
$6.21M Buy
64,190
+321
+0.5% +$30.3K 1.6% 6
2017
Q3
$5.67M Sell
63,869
-1,194
-2% -$90.9K 1.72% 4
2017
Q2
$4.72M Sell
65,063
-1,091
-2% -$73.3K 1.47% 6
2017
Q1
$4.31M Buy
66,154
+3,022
+5% +$190K 1.35% 9
2016
Q4
$3.95M Buy
63,132
+4,492
+8% +$274K 1.31% 8
2016
Q3
$3.7M Buy
58,640
+1,455
+3% +$94.2K 1.28% 10
2016
Q2
$3.54M Buy
57,185
+551
+1% +$33.6K 1.26% 11
2016
Q1
$3.23M Sell
56,634
-435
-0.8% -$24.2K 1.2% 14
2015
Q4
$3.38M Buy
57,069
+608
+1% +$35K 1.27% 12
2015
Q3
$3.07M Sell
56,461
-1,583
-3% -$103K 1.19% 15
2015
Q2
$3.9M Buy
58,044
+1,808
+3% +$118K 1.36% 8
2015
Q1
$3.29M Buy
56,236
+768
+1% +$46.4K 1.08% 18
2014
Q4
$3.63M Buy
55,468
+5
+0% +$315 1.19% 12
2014
Q3
$3.2M Sell
55,463
-1,942
-3% -$108K 1.09% 15
2014
Q2
$3.24M Buy
57,405
+1,507
+3% +$79.1K 1.05% 16
2014
Q1
$2.87M Sell
55,898
-1,053
-2% -$53.2K 1.02% 17
2013
Q4
$3.01M Buy
56,951
+233
+0.4% +$11.5K 1.08% 15
2013
Q3
$2.54M Sell
56,718
-1,478
-3% -$65.5K 1.03% 17
2013
Q2
$2.41M Buy
+58,196
New +$2.55M 0.92% 20

Other funds holding ABBV

Duncker Streett & Co's ABBV Position: Q1 2026 in Review

Duncker Streett & Co increased its AbbVie (ABBV) stake by 3.7% in Q1 2026, buying an estimated $584K and bringing the position to 74,644 shares worth $16.2M. The position accounts for 3.09% of the portfolio, ranked #5.

Duncker Streett & Co first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $16.5M in Q3 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Duncker Streett & Co held 74,644 shares of AbbVie worth $16.2M as of Q1 2026.
  • Duncker Streett & Co bought 2,632 AbbVie shares in Q1 2026, an estimated $584K.
  • AbbVie made up 3.09% of Duncker Streett & Co's portfolio in Q1 2026, its #5 holding.
  • Duncker Streett & Co first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Duncker Streett & Co's AbbVie position peaked at $16.5M in Q3 2025.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Duncker Streett & Co's 13F filing for Q1 2026, filed 29 Apr 2026.